X

Drug Profile

OVI 237

Alternative Names: 1843U89; BW 1843U89; GS 7904L; GW 1843U89; Liposomal OSI 7904; OSI-7904L; OVI-237

Latest Information Update: 16 Jun 2011

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OSI Pharmaceuticals
Developer OncoVista
Class Antimalarials; Antineoplastics
Mechanism of Action Thymidylate synthase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Biliary cancer; Cancer; Malaria

Most Recent Events

31 Mar 2011 Discontinued - Phase-II for Cancer in USA (unspecified route)
06 Dec 2007 OSI 7904L licensed to OncoVista worldwide
31 May 2004 Phase-II clinical trials in Biliary cancer in Europe (IV-infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com